Company Profile

PFIZER LTD.

NSE : PFIZERBSE : 500680ISIN CODE : INE182A01018Industry : Pharmaceuticals & DrugsHouse : Pfizer - MNC
BSE3164.55-5.8 (-0.18 % )
PREV CLOSE (Rs.) 3170.35
OPEN PRICE (Rs.) 3166.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 797
TODAY'S LOW / HIGH (Rs.)3145.00 3185.00
52 WK LOW / HIGH (Rs.)2489.1 3840
NSE3159.80 -26.9 (-0.84 % )
PREV CLOSE(Rs.) 3186.70
OPEN PRICE (Rs.) 3183.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 3159.80 (244 )
VOLUME 14290
TODAY'S LOW / HIGH(Rs.) 3144.00 3189.70
52 WK LOW / HIGH (Rs.)2491.1 3847.7

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.71
TTM EPS (Rs.) 93.79
P/E Ratio 33.74
Book Value (Rs.) 658.25
Face Value (Rs.) 10
MCap (Rs. in Mn) 144770.99
Price/Earning (TTM) 28.93
Price/Sales (TTM) 6.96
Price/Book (MRQ) 4.81
PAT Margin (%) 18.18
ROCE (%) 21.49
Incorporation Year : 1950

Management Info :

R A Shah - Chairman S Sridhar - Managing Director

Registered Office :

Address : The Capital, 1802/1901,Plot No.c-70, G Block,Bandra Kurla Complex, Bandra (East),
Mumbai,
Maharashtra-400051

Phone : 91 22 6693 2000

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
18Jun06-18-2019$Pfizer’s parent company acquires Array BioPharma Pfizer’s parent company ac

Pfizer’s parent company -- Pfizer Inc., USA, has acquired Array BioPharma, a biotechnology firm that specializes in cancer drugs. The company has offered $48 per share in cash for Array, putting $11.4 billion value on the company.

The proposed acquisition sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside the company’s existing expertise in breast and prostate cancers.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer’s parent company -- Pfizer Inc., USA, has acquired Arr..
28May05-28-2019$ Board recommends Dividend Board recommends Dividend
Pfizer Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 28, 2019, inter alia, has recommended a dividend of 225% (Rs. 22.50 per equity share of Rs. 10/- each) for the financial year ended March 31, 2019. The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on August 26, 2019.
Pfizer Ltd has informed BSE that the Board of Directors of the..
24May05-24-2019$CCI approves GSK, Pfizer consumer healthcare JV formation CCI approves GSK, Pfizer con

The Competition Commission of India (CCI) has approved the formation of a joint venture (JV) for consumer healthcare products by pharmaceutical giants Glaxosmithkline (GSK) and Pfizer. In December 2018, GSK had reached an agreement with Pfizer to combine their consumer health businesses into a new JV with combined sales of around $12.7 billion (around Rs 88,900 crore).

The proposed combination involves acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK. After the deal, GSK will have a majority controlling equity interest of 68 percent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 percent.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

The Competition Commission of India (CCI) has approved the form..
12Apr04-12-2019$Pfizer submits shareholding pattern Pfizer submits shareholding

Pfizer has submitted the Shareholding Pattern for the Period Ended March 31, 2019.

The above information is a part of company’s filings submitted to BSE.

Pfizer has submitted the Shareholding Pattern for the Period En..
08Mar03-08-2019$Pfizer informs about change in directorate Pfizer informs about change

Pursuant to regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Pfizer has informed that the Board of Directors of the Company has appointed Meena Ganesh (DIN: 00528252) as an Additional Independent Director of the Company, with effect from March 8, 2019 for a period of 5 years. The appointment of Meena Ganesh will be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company. Brief profile: Meena Ganesh does not hold any shares in the Company. None of the Directors are related to Meena Ganesh. Meena Ganesh is not debarred or disqualified from holding the office of Director by virtue of any order from MCA/SEBI or any such statutory authority.

The above information is a part of company’s filings submitted to BSE.

Pursuant to regulation 30(2) of the SEBI (Listing Obligations a..
Financials More
Rs. in Millions
QTR Mar 19 ANNUAL 19
Net Profit1094.74290.5
Gross Profit 1682.2 6599.1
Operating Profit 1864.47325.9
Net Sales 5356.620815
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Procter&Gamble Healt (BSE)
 3948.60 (2.48%)
M.Cap ( in Cr)
6554.43
Astrazeneca Pharma I (BSE)
 1886.40 (3.32%)
M.Cap ( in Cr)
4716.00
Dr. Reddys Lab (BSE)
 2590.00 (1.54%)
M.Cap ( in Cr)
43021.65
Torrent Pharma (BSE)
 1512.15 (0.97%)
M.Cap ( in Cr)
25586.90
IOL Chem & Pharma (BSE)
 192.05 (3.73%)
M.Cap ( in Cr)
1092.52
Shareholding Pattern More
MUTUAL FUNDS/UTI 8.65 %
PROMOTERS 63.92 %
FI/BANKS/INSURANCE 3.05 %
NON-INSTITUTION 19.9 %
FII 0.1 %
GOVERNMENT 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested